Virginia Tech
    • Log in
    View Item 
    •   VTechWorks Home
    • VTechWorks Archives
    • VTechWorks Administration
    • All Faculty Deposits
    • View Item
    •   VTechWorks Home
    • VTechWorks Archives
    • VTechWorks Administration
    • All Faculty Deposits
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    The effect of a connexin43-based Peptide on the healing of chronic venous leg ulcers: a multicenter, randomized trial.

    Thumbnail
    View/Open
    Publisher's Version (331.4Kb)
    Downloads: 188
    Date
    2015-01
    Author
    Ghatnekar, Gautam S.
    Grek, Christina L.
    Armstrong, David G.
    Desai, Sanjay C.
    Gourdie, Robert G.
    Metadata
    Show full item record
    Abstract
    The gap junction protein, connexin43 (Cx43), has critical roles in the inflammatory, edematous, and fibrotic processes following dermal injury and during wound healing, and is abnormally upregulated at the epidermal wound margins of venous leg ulcers (VLUs). Targeting Cx43 with ACT1, a peptide mimetic of the carboxyl-terminus of Cx43, accelerates fibroblast migration and proliferation, and wound reepithelialization. In a prospective, multicenter clinical trial conducted in India, adults with chronic VLUs were randomized to treatment with an ACT1 gel formulation plus conventional standard-of-care (SOC) protocols, involving maintaining wound moisture and four-layer compression bandage therapy, or SOC protocols alone. The primary end point was mean percent ulcer reepithelialization from baseline to 12 weeks. A significantly greater reduction in mean percent ulcer area from baseline to 12 weeks was associated with the incorporation of ACT1 therapy (79% (SD 50.4)) as compared with compression bandage therapy alone (36% (SD 179.8); P=0.02). Evaluation of secondary efficacy end points indicated a reduced median time to 50 and 100% ulcer reepithelialization for ACT1-treated ulcers. Incorporation of ACT1 in SOC protocols may represent a well-tolerated, highly effective therapeutic strategy that expedites chronic venous ulcer healing by treating the underlying ulcer pathophysiology through Cx43-mediated pathways.
    URI
    http://hdl.handle.net/10919/74988
    Collections
    • All Faculty Deposits [4206]
    • Scholarly Works, Biomedical Engineering and Mechanics [439]
    • Scholarly Works, Fralin Biomedical Research Institute at VTC [419]

    If you believe that any material in VTechWorks should be removed, please see our policy and procedure for Requesting that Material be Amended or Removed. All takedown requests will be promptly acknowledged and investigated.

    Virginia Tech | University Libraries | Contact Us
     

     

    VTechWorks

    AboutPoliciesHelp

    Browse

    All of VTechWorksCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    Log inRegister

    Statistics

    View Usage Statistics

    If you believe that any material in VTechWorks should be removed, please see our policy and procedure for Requesting that Material be Amended or Removed. All takedown requests will be promptly acknowledged and investigated.

    Virginia Tech | University Libraries | Contact Us